Conference: 22 – 23 November 2021
Venue: London, UK
Exploring the future of ocular drug development
4th Annual Ophthalmic Drugs Conference taking place on the 22nd and 23rd of November 2021, in London.
The global ophthalmic drug market is forecast to surpass $60 billion USD by 2025 with increasing focus from the industry on alternative delivery approaches and improving the effectiveness of the current repertoire of drugs in order to grow away from intravitreal injections and other surgical approaches to ocular therapy. With 50% of the global population predicted to have complications in their sight within the next few decades, ophthalmic medicine is set to become one of the biggest industries in pharmaceuticals.
As Europe’s leading Ophthalmic Drugs conference, we will explore new discoveries in the treatment of ocular disease, innovations in combination technologies, and the utterly unique challenges that are faced in the treatment of one of the most complex organs in the body.
This two-day agenda will offer peer-to-peer networking opportunities with leaders in the ophthalmic sphere, from Heads of Drug Development and Senior Directors of Ophthalmology, all the way to academic forerunners in the research into ocular therapy.
To register or for more information visit: www.ophthalmicdrugs.com/farmavitawl
BENEFITS OF ATTENDING:
- INSIGHT into the newest techniques in ocular drug design and delivery
- EXPLORE the impacts and applications of controlled release technologies
- LEARN how advanced medical devices are changing the face of combined therapy
- UNDERSTAND the latest developments in overcoming the challenge of treating such a complex organs
WHO SHOULD ATTEND:
- Ophthalmic Lead
- Clinical Director
- Senior Medical Advisor
- Franchise Head
- Business Manager
- Senior Scientist
- Senior Vice President
- Medical Director
- Therapeutic Area Head
- General Manager
- International Scientific Advisor